Reliable diagnostic and prognostic biomarkers for Parkinson’s disease are needed. Diagnosis is currently predominantly based on clinical symptoms. These clinical markers are limited in sensitivity and specificity and thus, making a definitive early diagnosis and predicting disease progression remain challenging. Chin-Hsien Lin, MD, PhD, National Taiwan University, Taipei, Taiwan, discusses the limitations of clinical subtyping and the potential benefits of introducing biofluid and genetic biomarkers to define specific patient subpopulations. This interview took place during the 2021 International Congress of Parkinson’s Disease and Movement Disorders.